Inoviv

Your go or no-go call is only as good as your standard. Ours are matched heavy and light pairs, built for absolute quantification.

Does your MS assay measure these as the same protein? One shared peptide gives all three a match.

Full-length, truncated or a variant: one shared peptide matches all three. Can your standard tell them apart?

Will your proteomics assay carry over from preclinical models into human samples? Some methods translate across species and sample types more easily than others, and that can shape your whole data package. This guide compares mass spectrometry and affinity approaches across discovery, preclinical and clinical stages. Download the free guide below.

How confident are you in the numbers behind your next go/no-go decision? Targeted LC-MS and affinity platforms take very different approaches to quantification, and that affects what you can compare across studies, sites and time points. This guide explains how the platforms differ on quantitation, specificity and reproducibility. Download the free guide below.

Know affinity, ELISA, Olink or Somalogic platforms, but less familiar with mass spectrometry? The two work in fundamentally different ways, and that affects what each can measure. This guide explains the difference in plain terms and compares discovery MS, targeted LC-MS and IP-MS with affinity platforms across seven criteria. Download the free guide below.